Results 301 to 310 of about 553,015 (386)

Justice for Placebo: Placebo Effect in Clinical Trials and Everyday Practice. [PDF]

Medicines (Basel)
Knezevic NN, Sic A, Worobey S, Knezevic E.   +3 more
europepmc   +1 more source

PERIOPERATIVE INTRAVENOUS LIDOCAINE INFUSION IN SPINE SURGERY: A RANDOMISED, PROSPECTIVE, DOUBLE‑BLIND, PLACEBO‑CONTROLLED STUDY

Dr M Sreya Santhoshi
openalex   +1 more source

Main factors associated with variability in the assessment of the objective response rate. A re‐analysis of the PHEREXA phase 3 clinical trial

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Local investigators (LIs) overestimate the objective response rate (ORR) in comparison to Blinded Independent Central Reviewers (BICR) in oncology. In this study, we re‐analysed data obtained in the PHEREXA trial (NCT01026142) with the following aims: i) to confirm at the single‐patient level the discrepancy observed by analysing ...
Gennaro Daniele, Tommaso Giovagnoli, Pierluigi Navarra, Cinzia Dello Russo   +3 more
wiley   +1 more source

What are set and setting: Reducing vagueness to improve research and clinical practice. [PDF]

J Psychopharmacol
Patch K, Smith WR.
europepmc   +1 more source

Zuranolone: A case study in (regulatory) rush to judgement?

British Journal of Clinical Pharmacology, EarlyView.
Abstract Sage, in collaboration with Biogen, submitted a new drug approval for zuranolone for postpartum depression (PPD) and major depressive disorder (MDD) in December 2022. In August 2023, the US Food and Drug Administration granted approval for PPD but denied approval for MDD.
Lisa Cosgrove, Milutin Kostic, Barbara Mintzes, Gianna D'Ambrozio, Allen Shaughnessy   +4 more
wiley   +1 more source

Acute and prolonged toxicity assessment of Cannabis sativa extract in rodents and lagomorphs. [PDF]

Toxicol Rep
Costa AC, Gasparotto A, Garcia AAK, Pereira CAC, Lourenço ELB, Joaquim HPG.   +5 more
europepmc   +1 more source

Pharmacokinetic‐pharmacodynamic modelling of risankizumab using chronic plaque psoriasis real‐world data

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Risankizumab is a high‐cost biologic treatment for chronic plaque psoriasis, an immune‐mediated inflammatory disease presenting with painful red scaly skin lesions. Inter‐individual heterogeneity in treatment response may be better addressed with personalised rather than fixed dosing. We sought to develop a pharmacokinetic/pharmacodynamic (
Charlotte M. Thomas, Jessica Ruoheng Wei, David Baudry, Zehra Arkir, Bola Coker, Tejus Dasandi, Kingsley Powell, Monica Arenas‐Hernandez, Jenny Leung, Krystal Rawstron, Chioma Nwaogu, Richard Woolf, Andrew E. Pink, Jonathan Barker, Joseph F. Standing, Catherine H. Smith, Satveer K. Mahil   +16 more
wiley   +1 more source

Revolutionizing Chinese medicine granule placebo with a machine learning four-color model. [PDF]

Chin Med
Teng T, Zhang J, Miao P, Liang L, Song X, Liu D, Zhang J.   +6 more
europepmc   +1 more source

The placebo and design research [PDF]

, 2012
Cash, Philip
core  

GLP‐1 agonists and the gut microbiome: A bidirectional relationship

British Journal of Clinical Pharmacology, EarlyView.
Abstract Glucagon‐like peptide‐1 (GLP‐1) receptor agonists have transformed the management of type 2 diabetes mellitus (T2DM) and obesity, yet their interactions with the gut microbiome remain an emerging frontier in pharmacological and metabolic research.
Srinivas Kamath, Nicole S. L. Chan, Paul Joyce   +2 more
wiley   +1 more source